Review Article

Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Table 3

Completed clinical trials of bevacizumab combined with chemotherapy in ovarian cancer.

Trial numberPhaseChemotherapyStage of the diseaseNumber of patientsOutcomes

NCT00127920 (AV53206s) [39]IICarboplatin + paclitaxel Newly diagnosed stage III/IV20CR: 30%
PR: 50%
NCT00072566 (NCI-5789) [40]IIMetronomic cyclophosphamidePlatinum-sensitive recurrent70CR: 0
PR: 24%
MPFS: 7.2 (m)
MOS: 16.9 (m)
NCT00129727 (OVCA) [41]IICarboplatin + paclitaxel + bevacizumab + maintenance bevacizumabNewly diagnosed stage ≥ IC62CT:
CR: 56%
PR: 22%
Ca-125:
CR: 89%
PR: 7%
NCT00343044 (3040200, AVF3648s)*IITopotecanPlatinum-resistant recurrent EOC, PPC, FTCN/AN/A

CR: complete response, PR: partial response, MPFS: median progression-free survival, m: months, MOS: median overall survival (months), EOC: epithelial ovarian cancer, PPC: primary peritoneal cancer, FTC: fallopian tube cancer.
*Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.